Dr Joseph Sinkule named president and COO of Compass Biotechnologies

 
• By Gemma Sharman

Compass Biotechnologies has appointed Dr Joseph Sinkule president and chief operating officer. He recently played a leading role in directing the company towards the bio betters, generic drug markets and development of biosimiliar blockbuster products. In his new role, Dr Sinkule will take charge of the hepatitis drug development programme of C-Pharma, a subsidiary of Compass.

Compass Biotechnologies has appointed Dr Joseph Sinkule president and chief operating officer. He recently played a leading role in directing the company towards the bio betters, generic drug markets and development of biosimiliar blockbuster products. In his new role, Dr Sinkule will take charge of the hepatitis drug development programme of C-Pharma, a subsidiary of Compass.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.